Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
172 hedge funds and large institutions have $3.37B invested in Intercept Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 65 increasing their positions, 51 reducing their positions, and 22 closing their positions.
33% more call options, than puts
Call options by funds: $211M | Put options by funds: $159M
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
16% more capital invested
Capital invested by funds: $2.91B → $3.37B (+$464M)
3% more funds holding
Funds holding: 167 → 172 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$50.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.5M |
| 4 |
Millennium Management
New York
|
+$13.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$60M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$36.1M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.1M |
| 4 |
ECM
Element Capital Management
New York
|
-$13.6M |
| 5 |
CCI
Columbus Circle Investors
|
-$12.4M |
ICPT Hedge Fund Activity: Q3 2016 in Review
172 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2016, worth a combined $3.37B — up 16% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ICPT positions and 22 closed out — a net gain of 6 holders — while 65 added to existing stakes and 51 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $66.3M. The largest seller was Ameriprise, cutting an estimated $60M.
- 172 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2016, up from 167 in Q2 2016.
- Funds reported $3.37B of Intercept Pharmaceuticals, Inc. stock for Q3 2016, up 16% quarter-over-quarter.
- 28 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2016 and 22 closed out, a net change of +6 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2016 was Citadel Advisors, an estimated $66.3M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2016 was Ameriprise, an estimated $60M sold.
Based on aggregated 13F filings for Q3 2016.